Trial Profile
A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects with Hypertension Requiring Antihypertensive Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Feb 2021
Price :
$35
*
At a glance
- Drugs Amlodipine (Primary) ; Celecoxib (Primary)
- Indications Hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Kitov Pharmaceuticals; Purple Biotech
- 31 May 2018 U.S. Food and Drug Administration (FDA) has approved Consensi™ (amlodipine and celecoxib) oral tablets for treatment of osteoarthritis pain and hypertension, according to a Kitov Pharmaceuticals media release.
- 02 Oct 2017 According to a Kitov Pharmaceuticals media release, U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for KIT-302, the FDA under the Prescription Drug User Fee Act (PDUFA), has set a target date of May 31, 2018 to complete its review.
- 31 Jul 2017 According to a Kitov Pharmaceuticals media release, company has submitted a NDA to the U.S. FDA for KIT-302 and are on track to meet anticipated Prescription Drug User Fee Act (PDUFA) dates with respect to FDA filing the NDA in the third quarter of 2017, and rendering a decision on approval for marketing of KIT-302 during the second quarter of 2018